Skip to content
MarketScale
‹ Back to IndustriesHealthcare

TPC’s Interventional Cardiology (IC) Program Engages in Partnerships That Deliver Greater Value for its Membership

For small, stand-alone hospitals, remaining profitable while providing the best patient care can be challenging. TPC provides a platform for strategic partnerships that can help these independent entities reduce costs and improve patient outcomes. Working collaboratively, TPC Member hospitals achieve more together, collectively negotiating for services and supplies to increase their financial, operational and clinical…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

For small, stand-alone hospitals, remaining profitable while providing the best patient care can be challenging. TPC provides a platform for strategic partnerships that can help these independent entities reduce costs and improve patient outcomes. Working collaboratively, TPC Member hospitals achieve more together, collectively negotiating for services and supplies to increase their financial, operational and clinical performance.

TPC programs deliver opportunities through Member-driven custom contracting, providing access to clinically acceptable products purchased in aggregate to decrease costs. As part of the process, from contract period to contract period, TPC evaluates marketplace opportunities in existing categories, using specific, predetermined criteria to ascertain the most superior products at the best value. By remaining supplier agnostic, TPC Members have the flexibility to comfortably disrupt the status quo and shift between suppliers to drive the highest value back to the membership.

When it comes to PPI, the TPC collaborative model has proven results in reducing supply chain expenses. A highly Member-engaged initiative that has yielded impressive results, TPC’s Interventional Cardiology (IC) program drove $1.2 million in savings across the membership in 2018, representing 11% of total IC spend. And since the IC initiative’s 2010 inception, over $9.98 million has been saved by TPC Members. TPC continues to meet its commitment with the category’s preferred suppliers, with Members maintaining greater than 80% compliance. TPC is the epitome of a value-based partnership of community-based hospitals working together as a single system.

Stronger Together. Superior Results.

To learn more about membership click here.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Recent advancements in healthcare, including gene therapies, early detection methods, and GLP-1 drugs, are influencing enterprise healthcare procurement strategies. These innovations are impacting benefit plan adjustments and procurement decision-making processes. The healthcare industry is experiencing a notable shift due to FDA-cleared treatments and predictive diagnostics.

  • 01Gene therapies and early detection methods are transforming healthcare procurement.
  • 02FDA-cleared treatments are prompting shifts in benefit plans.
  • 03Advancements are accelerating decision-making in healthcare procurement.

Jul 14, 2026

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512